Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OH2 + capecitabine
- Development stage
- Unknown
- Lead developer
- Shanghai Sunway Biotech
- Modality
- Small Molecules, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Oral, Intratumoral
01
Overview
This entry refers to a **combination therapy of OH2 (an oncolytic virus, also described as recombinant human herpes simplex virus type 1 or rHSV1) and capecitabine (an orally administered small molecule prodrug of 5-fluorouracil)**. Capecitabine is an antimetabolite chemotherapeutic used in various solid tumors—most notably colorectal, gastric, and breast cancer—where it blocks DNA synthesis by incorporating 5-fluorouracil metabolites into DNA/RNA, leading to cytotoxicity against rapidly dividing cells[4][5][6]. OH2 is an engineered oncolytic virus designed to selectively replicate within and lyse tumor cells, and may also stimulate anti-tumor immune responses. The combination is being clinically investigated for synergistic anti-tumor effects; capecitabine may enhance the efficacy of oncolytic viruses via immunomodulation and by upregulating thymidine phosphorylase, which activates the prodrug to 5-FU within tumors[5].
- Other names
- OH2OH-2OH 2capecitabine
02
Targets
TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on OH2 + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OH2 + capecitabine.